Boehringer Ingelheim and Eli Lilly have secured approval from the European Commission (EC) for Jardiance (empagliflozin) to treat adults with chronic kidney disease (CKD).

Empagliflozin, an oral, once-daily, and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, was also approved in the EU to treat type 2 diabetes (T2D) and heart failure.

It is claimed to be the first T2D drug to feature cardiovascular death risk reduction data for people with T2D and cardiovascular disease on its label in various countries.

Lilly diabetes and obesity global medical affairs senior vice-president Leonard Glass said: “We look forward to continuing conversations with other regulatory bodies worldwide so that empagliflozin can be made available for as many people living with these conditions as quickly as possible.”

The latest approval is based on data from EMPA-KIDNEY, which is a randomised, double-blind, multinational, and placebo-controlled clinical study.

This trial assessed the effect of empagliflozin on kidney disease progression and cardiovascular mortality risk in 6,609 participants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Claimed to be the largest SGLT2 inhibitor trial in CKD so far, the study demonstrated a significant benefit of empagliflozin in lowering the relative risk of kidney disease progression or cardiovascular death by 28% compared with placebo in people suffering from CKD.

Furthermore, the trial showed a statistically significant relative risk reduction of hospitalisation for any cause by 14% compared with a placebo.

Boehringer Ingelheim human pharma head, Carinne Brouillon said: “As we deepen our knowledge in interconnected cardio-renal-metabolic conditions, we are very excited about the approval and the potential for empagliflozin to play an essential role in helping patients, their physicians and healthcare systems.”